News NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
21.99 ^USD	-0.81%		+33.52%	+47.29%

May. 02	NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue	MT
May. 02	BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NovoCure Shares Steady After Reporting Narrower Q1 Loss, Higher Revenue	May. 02	MT
BioPharma Credit Enters $400 Million Loan Agreement with Novocure Luxembourg	May. 02	MT
BioPharma Credit agrees USD400 million loan for oncology firm Novacure	May. 02	AN
Transcript : NovoCure Limited, Q1 2024 Earnings Call, May 02, 2024	May. 02
NovoCure: Q1 Earnings Snapshot	May. 02	AQ
Earnings Flash (NVCR) NOVOCURE Reports Q1 Revenue $138.5M, vs. Street Est of $131.5M	May. 02	MT
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon	May. 02	BU
Novocure Reports First Quarter 2024 Financial Results	May. 02	BU
NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Novocure Enters into New Five-Year Up to $400 Million Committed Senior Secured Credit Facility with Funds Managed by Pharmakon Advisors, LP	May. 02	CI
NovoCure Limited announced that it expects to receive $400 million in funding	May. 01	CI
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024	Apr. 24	BU
NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	Apr. 24	CI
NovoCure : Corporate responsibility report	Apr. 22	PU
Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	Apr. 10	MT
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research Annual Meeting 2024	Apr. 08	AQ
NovoCure Says New Data Show TTFields' Potential Therapeutic Effects in Pancreatic Cancer	Apr. 05	MT
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024	Apr. 05	BU
Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating	Apr. 03	MT
Novocure to Report First Quarter 2024 Financial Results	Apr. 01	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Summary

Filters